Legal Issues Behind It, IBIO Stock May Be a Long Play For Risk-Tolerant Investors

iBio remains a dark horse in the ongoing development of Covid-19 vaccines. But an intriguing new candidate and a resolution of intellectual property issues makes a long, albeit small position in IBIO stock justified for risk-tolerant investors.